BCR/ABL amplification in CML blast crisis following STI571 administration.

被引：0
作者：
Campbell, LJ
Patsouris, C
Rayeroux, KC
Somana, K
Januszewicz, H
机构：
[1] St Vincents Hosp, Victorian Canc Cytogenet Serv, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4435
引用
收藏
页码：185B / 185B
页数：1
相关论文
共 50 条
[41]   BCR/ABL阳性细胞对STI571耐药机制的研究进展 [J].
张磊 .
国外医学输血及血液学分册., 2002, (03) :226-228
[42]   The CNS is a sanctuary for leukemic cells in mice receiving STI571 for Bcr/Abl-induced leukemia. [J].
Wolff, NC ;
Richardson, JA ;
Egorin, M ;
Ilaria, RL .
BLOOD, 2002, 100 (11) :741A-741A
[43]   Effects of the bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on leukemic cells in vitro. [J].
Chandra, J ;
Mow, B ;
Weisberg, E ;
Griffin, J ;
Sausville, EA ;
Tefferi, A ;
Kaufmann, SH .
CLINICAL CANCER RESEARCH, 2001, 7 (11) :3768S-3769S
[44]   Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells [J].
Gottschalk, S ;
Anderson, N ;
Hainz, C ;
Eckhardt, SG ;
Serkova, NJ .
CLINICAL CANCER RESEARCH, 2004, 10 (19) :6661-6668
[45]   HETEROGENEITY IN EXPRESSION OF THE BCR-ABL FUSION TRANSCRIPT IN CML BLAST CRISIS [J].
ANDREWS, DF ;
COLLINS, SJ .
LEUKEMIA, 1987, 1 (10) :718-724
[46]   Imatinib mesylate (STI571) for myeloid malignancies other than CML [J].
Krystal, GW .
LEUKEMIA RESEARCH, 2004, 28 :S53-S59
[47]   In vitro effects of PS-341 alone and in combination with STI571 in Bcr-Abl positive cell lines both sensitive and resistant to STI571. [J].
Gatto, SR ;
Scappini, B ;
Verstovsek, S ;
Milella, M ;
Onida, F ;
Ball, G ;
Kantarjian, HM ;
Keating, MJ ;
Cortes, JE ;
Beran, M .
BLOOD, 2001, 98 (11) :101A-101A
[48]   Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells [J].
Thiesing, JT ;
Ohno-Jones, S ;
Kolibaba, KS ;
Druker, BJ .
BLOOD, 2000, 96 (09) :3195-3199
[49]   The ABL-kinase inhibitor STI571 causes BCR-ABL independent resistance in breast cancer cell lines. [J].
Burchert, A ;
Jaenike, M ;
Schmidt, M ;
Brendel, C ;
Rieder, H ;
Neubauer, A .
BLOOD, 2001, 98 (11) :255B-255B
[50]   Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571 [J].
Corbin, AS ;
Buchdunger, E ;
Pascal, F ;
Druker, BJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (35) :32214-32219
12345